181 related articles for article (PubMed ID: 9927611)
21. DNA topoisomerase II inhibitors induce macrophage ABCA1 expression and cholesterol efflux-an LXR-dependent mechanism.
Zhang L; Jiang M; Shui Y; Chen Y; Wang Q; Hu W; Ma X; Li X; Liu X; Cao X; Liu M; Duan Y; Han J
Biochim Biophys Acta; 2013 Jun; 1831(6):1134-45. PubMed ID: 23466610
[TBL] [Abstract][Full Text] [Related]
22. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
23. Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells.
Anderson H; Roberge M
Cell Growth Differ; 1996 Jan; 7(1):83-90. PubMed ID: 8788036
[TBL] [Abstract][Full Text] [Related]
24. FK506 restores sensitivity of thymic lymphomas to calcium-mediated apoptosis and the inducible expression of Fas ligand.
Kalas W; Matuszyk J; Ziolo E; Strzadala L
Anticancer Res; 2003; 23(2B):1613-7. PubMed ID: 12820430
[TBL] [Abstract][Full Text] [Related]
25. An Sp1 binding site involves the transcription of the Fas ligand gene induced by PMA and ionomycin in Jurkat cells.
Chou CF; Peng HW; Wang CY; Yang YT; Han SH
J Biomed Sci; 2000; 7(2):136-43. PubMed ID: 10754388
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.
Mitsiades N; Yu WH; Poulaki V; Tsokos M; Stamenkovic I
Cancer Res; 2001 Jan; 61(2):577-81. PubMed ID: 11212252
[TBL] [Abstract][Full Text] [Related]
27. Synergistic action of protein kinase C theta and calcineurin is sufficient for Fas ligand expression and induction of a crmA-sensitive apoptosis pathway in Jurkat T cells.
Villunger A; Ghaffari-Tabrizi N; Tinhofer I; Krumböck N; Bauer B; Schneider T; Kasibhatla S; Greil R; Baier-Bitterlich G; Uberall F; Green DR; Baier G
Eur J Immunol; 1999 Nov; 29(11):3549-61. PubMed ID: 10556809
[TBL] [Abstract][Full Text] [Related]
28. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
29. The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication.
Pastor N; Domínguez I; Orta ML; Campanella C; Mateos S; Cortés F
Mutat Res; 2012; 738-739():45-51. PubMed ID: 22921906
[TBL] [Abstract][Full Text] [Related]
30. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16).
Long BH
Semin Oncol; 1992 Apr; 19(2 Suppl 6):3-19. PubMed ID: 1329225
[TBL] [Abstract][Full Text] [Related]
32. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells.
Fattman CL; Allan WP; Hasinoff BB; Yalowich JC
Biochem Pharmacol; 1996 Aug; 52(4):635-42. PubMed ID: 8759037
[TBL] [Abstract][Full Text] [Related]
33. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Sehested M; Jensen PB
Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
van Hille B; Etiévant C; Barret JM; Kruczynski A; Hill BT
Anticancer Drugs; 2000 Nov; 11(10):829-41. PubMed ID: 11142691
[TBL] [Abstract][Full Text] [Related]
35. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
Holm B; Sehested M; Jensen PB
Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
[TBL] [Abstract][Full Text] [Related]
36. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation.
Shinohara H; Yagita H; Ikawa Y; Oyaizu N
Cancer Res; 2000 Mar; 60(6):1766-72. PubMed ID: 10749152
[TBL] [Abstract][Full Text] [Related]
37. Efficient induction of chromosome-type aberrations by topoisomerase II inhibitors closely associated with stabilization of the cleavable complex in cultured fibroblastic cells.
Suzuki H; Ikeda T; Yamagishi T; Nakaike S; Nakane S; Ohsawa M
Mutat Res; 1995 May; 328(2):151-61. PubMed ID: 7739599
[TBL] [Abstract][Full Text] [Related]
38. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene.
Guan B; Yue P; Clayman GL; Sun SY
J Cell Physiol; 2001 Jul; 188(1):98-105. PubMed ID: 11382926
[TBL] [Abstract][Full Text] [Related]
39. Differentiation of U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase II inhibitors with different mechanisms of action.
Pérez C; Vilaboa NE; García-Bermejo L; de Blas E; Creighton AM; Aller P
J Cell Sci; 1997 Feb; 110 ( Pt 3)():337-43. PubMed ID: 9057086
[TBL] [Abstract][Full Text] [Related]
40. Induction of FAS ligand expression in a human hepatoblastoma cell line by HCV core protein.
Ruggieri A; Murdolo M; Rapicetta M
Virus Res; 2003 Nov; 97(2):103-10. PubMed ID: 14602201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
